© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to November
oral MET kinase inhibitor
approved for clinical use in NSCLC
internal HTS and SBDD
Clinical Cancer Research
9. The Merck KGaA MET kinase inhibitor, tepotinib, was approved earlier this year for METex14 positive NSCLC patients, and is administered once-daily in contrast to capmatinib, which was approved in 2020. Both…
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.